Cell and gene therapies are nothing short of a revolution in medicine that holds promise across oncology, cardiology, endocrinology, hematology and more. Many gene therapies already offer breakthroughs in care, or even cure lifelong diseases. And the number of cell and gene therapies are poised to grow exponentially in coming years.
The coming era of cell and gene therapy is not without its challenges, but digital can play a big role in smoothing the road to adoption.
1 Biospace. Cell and Gene Therapy Market Size, Growth, Trends, Forecast Report 2022-2030. August 11, 2022.
2 Biospace. Cell and Gene Therapy Market Size, Growth, Trends, Forecast Report 2022-2030. August 11, 2022.
3 Wong CH. Li D., Wang N. Gruber J. Conti RM. Lo AW. Estimating the Financial Impact of Gene Therapy in the U.S. National Bureau of Economic Research. April 2021.
PATIENT ACCESS
With the average cost of a gene therapy somewhere between $1 and $2 million per dose,4 securing coverage for patients can be a huge barrier. Even with coverage, out-of-pocket costs can be a hurdle.
FEAR OF THE NEW
Despite the groundbreaking nature of these therapies, many patients feel discomfort with the concept of gene therapy, either because they don’t understand the technology or are skeptical about being among the first to try a novel treatment.
LONG-TERM MONITORING
Because gene therapy represents a permanent or long-lasting change to the body, the FDA requires a 15 year period of monitoring for long-term follow up. It’s equally important to have long-term real-world data to convince skeptical patients and HCPs.
PAYER HURDLES
The high price of cell and gene therapies are forcing biopharma companies to rewrite their playbook for negotiating with payers. To support inclusion, drugmakers need to show robust real-world data on the drug’s value to the healthcare system, quality of life, productivity and more.
Read the case study to learn how BrightInsight took CSL Behring from project kickoff to B SUPPORT app launch in just four months.
Read Now
Easy-to-use tools, including document exchange, help patients track and manage eligibility assessment, prior authorization, as well as navigate financial assistance and digital copay support to reduce out-of-pocket barriers.
Patients may have difficulty accessing accurate information about their rare disease. Personalized content, including PSP care team support, provides timely information and encouragement to guide patients through the gene therapy journey for an optimal experience.
Configurable digital tools—including medication and appointment reminders, patient journals, symptom and adverse event tracking, quality of life surveys, community support and more—can help patients track their condition before and after gene therapy.
Patient apps provide biopharma companies with the real-world data they need to understand and address issues in the patient journey, and capture insights to show a compelling value picture to payers to support outcomes-based payment models.
Contact us today to start a conversation about how BrightInsight can help on your digital health journey.
Contact us